MSD Archives -

This episode of the pharmaphorum podcast is the first in an occasional series focused on patient engagement that’s

Patient engagement strategies: the pharmaphorum podcast

https://pharmaphorum.com/patients/patient-engagement-strategies/

Oncology/ Sales and Marketing/ Views & Analysis/ Views & Analysis/ Views and analysis

The top 5 pharma M&A deals of 2020

George Underwood Gilead, J&J, Johnson and Johnson, M&A, Merck & Co, MSD, Sanofi 0 Comment

2020’s M&A activity hasn’t quite reached the heights of last year’s, where two pharma mega-mergers – BMS’ buyout

The top 5 pharma M&A deals of 2020

https://pharmaphorum.com/views-and-analysis/the-top-5-pharma-ma-deals-of-2020/

Patients/ Views & Analysis/ Views and analysis

How companies can encourage more diversity and inclusion in pharma

mike.hammerton@pharmaphorum.com diversity, Merck & Co, MSD 0 Comment

September is Global Diversity and Inclusion month – David Peacock, managing director of MSD in the UK shares

How companies can encourage more diversity and inclusion in pharma

https://pharmaphorum.com/views-analysis-patients/how-companies-can-encourage-more-diversity-and-inclusion-in-pharma/

Market Access/ Sales and Marketing/ Views & Analysis/ Views & Analysis/ Views and analysis

MSD’s David Peacock on moving UK healthcare forward

mike.hammerton@pharmaphorum.com coronavirus, COVID-19, Merck, Merck & Co, MSD, NHS, UK, UK Leaders 0 Comment

David Peacock has worked across the world for MSD and other companies, and has now taken the helm

MSD’s David Peacock on moving UK healthcare forward

https://pharmaphorum.com/views-analysis-sales-marketing/msds-david-peacock-on-moving-uk-healthcare-forward/

News/ News/ Oncology

EU regulators approve AstraZeneca’s Lynparza in pancreatic cancer

Richard Staines AstraZeneca, Clovis, GlaxoSmithKline, MSD, Pfizer 0 Comment

The European Commission has approved AstraZeneca and MSD’s Lynparza (olaparib) in pancreatic cancer patients with a certain mutation. Approval in metastatic

EU regulators approve AstraZeneca’s Lynparza in pancreatic cancer

https://pharmaphorum.com/news/eu-regulators-approve-astrazenecas-lynparza-in-pancreatic-cancer/

News/ News/ Oncology

NICE rejects MSD/Pfizer’s combination in untreated kidney cancer

Richard Staines cancer, kidney cancer, market access, MSD, NICE, Pfizer, renal cell carcinoma 0 Comment

NICE said “no” to NHS funding for a combination of MSD’s Keytruda (pembrolizumab) immunotherapy and Pfizer’s Inlyta (axitinib)

NICE rejects MSD/Pfizer’s combination in untreated kidney cancer

https://pharmaphorum.com/news/nice-rejects-msd-pfizers-combination-in-untreated-kidney-cancer/

Market Access/ News/ News/ News/ Oncology

NICE backs Lynparza across the board for BRCA+ovarian cancer

Phil Taylor AstraZeneca, Lynparza, MSD, Oncology, ovarian cancer, PARP inhibitor 0 Comment

AstraZeneca and MSD’s Lynparza has become the first PARP inhibitor to be recommended for all lines of maintenance

NICE backs Lynparza across the board for BRCA+ovarian cancer

https://pharmaphorum.com/news/nice-backs-lynparza-across-the-board-for-brca-ovarian-cancer/

News/ News/ Oncology

AZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatment

George Underwood AstraZeneca, Calquence, chronic lymphocytic leukaemia, CLL, Lynparza, Merck & Co, MSD, ovarian cancer, PARP 0 Comment

AstraZeneca and MSD’s Lynparza has scored its second Phase 3 win in the space of a week, this

AZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatment

https://pharmaphorum.com/news/az-msd-parp-inhibitor-ovarian-cancer/

Market Access/ News/ News/ News/ News/ Oncology/ Patients/ Top stories

MSD’s Keytruda plus chemo backed by NICE for lung cancer

Phil Taylor Keytruda, MSD, NICE, Non-small cell lung cancer, Oncology 0 Comment

Merck & Co/MSD’s Keytruda can be provided via the Cancer Drugs Fund for first-line treatment of non-small cell

MSD’s Keytruda plus chemo backed by NICE for lung cancer

https://pharmaphorum.com/news/msds-keytruda-plus-chemo-backed-by-nice-for-lung-cancer/

Trending

MSD

Login